Deals
Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Surface Oncology announced it has secured a debt financing facility for up to $25 million from K2 HealthVentures, a healthcare-focused specialty finance company.
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, reported financial and operating results for the fourth quarter and fiscal year ended August 31, 2019 and provided a business update.
Sorrento Therapeutics, Inc., confirmed that on November 23, 2019, it received an unsolicited, non-binding term sheet proposal submitted by two biopharmaceutical companies, to acquire all of the issued and outstanding shares of the Company for between $3.00 and $5.00 per share in cash.
Agreement provides Enochian with exclusive rights to develop and commercialize a HBV treatment with a novel mechanism of action
Summary of webcast with Key Opinion Leaders on Indolent Systemic Mastocytosis
BONE THERAPEUTICS informs its shareholders and holders of warrants and convertible bonds of the Company that an extraordinary general shareholder meeting will be held on Thursday 12 December 2019 at 10am CET, at the Company’s registered offices, rue Auguste Piccard 37, 6041 Gosselies, Belgium.
PCI Biotech, a cancer focused biopharmaceutical company announces its third quarter 2019 result.
Certain of Recipharm’s larger institutional shareholders, Första AP-fonden, Lannebo Fonder and Fjärde AP-fonden, support the cash offer for Consort Medical and have undertaken to fully support and vote in favour of a rights issue at a forthcoming general meeting of Recipharm and have also undertaken to subscribe for an amount corresponding to at least their respective pro rata share in a rights issue of SEK 2,000 million.
With the Thanksgiving holiday fast-approaching in the United States, some investors are giving their thanks to five different pharma companies that became available on the stock exchange this month with an initial public offering.
Motif Bio plc announces that formal notice was given by the Company to Nasdaq on November 25, 2019 of the intention to voluntarily delist the Company’s American Depository Shares and listed warrants from the Nasdaq Capital Market.